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between our patient group and Blumberg and associ-
ates patient group, which is composed mostly of thy-
mic carcinomas as described by Rosai and associ-
ates.21 •22 The difference of clinical implication of the 
Masaoka staging system between these 2 studies might 
reflect the oncologic distinction between thymomas 
and thymic carcinomas. 
In conclusion, the Masaoka staging system and 
involvement of the great vessels were independent prog-
nostic factors in our series of thymomas. Involvement of 
the great vessels was also an independent prognostic 
factor in patients with stage III disease. Thus the cate-
gory of stage III disease in the Masaoka staging system 
is a heterogeneous group, consisting of 2 subgroups 
with distinct prognosis depending on involvement of the 
great vessels. Involvement of the great vessels was sug-
gested to be an essential factor in determining the ther-
apeutic modality for stage III thymoma. 
We thank Dr Toshiro Nishida for help in statistical analysis. 
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Commentary 
The article by Okumura and associates should be 
compared with that of Blumberg and colleagues! with 
regard to the prognostic significance of thymic tumors 
involving the great vessels. Both articles seem to yield 
the same results, despite the fact that in the current pub-
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lication, thymic "carcinomas" were excluded, whereas 
in the Blumberg article only thymic "carcinomas" were 
included. 
Why this discrepancy? Probably because of a lack of 
agreement and uniformity in the nomenclature and 
classification of thymic tumors, Since 1916, no fewer 
than 21 different histologic classifications of thymic 
tumors have been proposed,2 
The classification used by the current authors is 37 
years 0ld3 and deals only with the proportions of 
epithelial cells and lymphocytes, rather than focusing 
in the true thymic tumor cell, the epithelial cell, 
Earlier on, pathologists did not address the signifi-
cance of microscopy in the determination of benign 
versus malignant lesions, deferring to the surgeon's 
observation as to whether or not gross invasion of sur-
rounding structures had occurred, However, in the past 
15 years there have been a flood of articles dealing with 
thymic carcinoma based on microscopy.4 
While the microscopic characterization of thymic car-
cinoma is being debated,S-7 the evidence to date tends to 
support the newer Miiller-Hermelink classification. 
I agree with Shimosat08 in deploring the lack of 
"standard" World Health Organization histologic clas-
sification of thymic tumors, as already exists for many 
other tumors, including lung tumors. 
This brings up the validity and applicability of the 
Masaoka staging system.9 Originally, it was intended 
for "thymomas" (bland cytology) only. However, with 
a more comprehensive view of thymic tumor patholo-
gy, the next logical move would be the institution of a 
TNM staging system to support the Masaoka system. 
Interestingly enough, such a TNM system has already 
been proposed by Yamakawa and colleagues, lO in an 
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article in which Masaoka was a coauthor, and subse-
quently was also proposed by Tsuchiya and associ-
ates l ! in 1994. 
REFERENCES 
Paul A. Kirschner, MD 
New York, NY 
1. Blumberg 0, Burt ME. Bains MS, et al. Thymic carcinoma: cur-
rent staging does not predict prognosis. J Thorac Cardiovasc Surg 
1998;115:303-9. 
2. Shimosato Y, Mukai K. Atlas of tumor pathology, third series, 
fascicle 21. Tumors of the mediastinum. Washington [DC] 
Armed Forces Institute of Pathology; 1997. p. 34-5. 
3. Bernatz PE, Harrison EG. Clagett OT. Thymoma; a clinicopatho-
logic study. J Thorac Cardiovasc Surg 1961;42:424-44. 
4. Kirchner T, Milller-Hermelink HK. New approaches to the diag-
nosis of thymic epithelial tumors. In: Fenoglio-Preiser CM, Wolff 
M, Rilke F, editors. Progress in surgical pathology, vol 10, New 
York: Field and Wood Medical Publishers; 1989. p. 167-89. 
5. Dawson A, Ibrahim NBN, Gibbs AR. Observer variation in the 
histopathological classification of thymoma. Correlation with 
prognosis. J Clin PathoI1994;47:519-23. 
6. Quintanilla-Martinez L, Wilkins EW, Choi N, et al. Thymoma: 
histologic subclassification is an independent prognostic factor. 
Cancer 1994;74:606-17. 
7. Close PM. Kirchner T, Uys CJ, et al. Reproducibility of a histo-
genetic classification of thymic epithelial tumors. Histopathology 
1995;26:339-43. 
8. Shimosato Y. Controversies surrounding the subclassification of 
thymoma [editorial]. Cancer 1994;74:542-4. 
9. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of 
thymomas with special reference to their clinical stage. Cancer 
1981 ;48:2485-92. 
10. Yamakawa Y, Masaoka A, Hashimoto T, et al. A tentative tumor-
node-metastasis classitication of thymoma. Cancer 1991 ;68: 1980-7. 
11. Tsuchiya R, Koga K, Matsano Y, et al. Thymic carcinoma: propos-
al for pathological TNM and staging. Pathol Int 1994;44:505-12. 
12/1196209 
